Replies to post #18013 on Oncolix Inc. (fka ONCX)

[reaper247]

Pfffttt namtae,

The conversation I was having was about the notes. Someone then changes the topic to total debt and accuses me of misleading people. Its silly.

I did forget that when ONCX renegotiated the notes (as predicted,) I forgot to factor in additional financing. I acknowledged my mistake and thanked you specifically for reminding me.

Not sure how anyone can accuse me of posting "misinformation."

How does any non insider have knowledge of when we receive updates on Prolanta and whether those updates (if any) are positive or negative to justify a much higher share price

An update on Prolanta trials is a FLE that is anticipated by everyone here. I am speculating that since the note holders were willing to renegotiate the notes, provide additional funding and have interest accrued until April 2019, there is likely positive news coming shortly.

Further, to suggest a .50 - $1.00 share price (up to $1billion market cap) on Phase 1 data is ridiculous!!

I stated that given the PPS and O/S, ONCX is undervalued when looking at the market cap.

If you don’t like my numbers, put your own up for scrutiny.

I ran through scenarios featuring O/Ss of 200M 300M and 500M.

NASDAQ listing in 2019? lol Even with fairly good phase 1 results sometime in 2019, Oncolix would need to raise a ton of cash to qualify, among other items.

I don’t understand. We are expecting results on the second cohort of phase 1 any day now. Why do we need to wait until 2019 to see progress?

Also, why would Oncolix need to raise a ton of cash to qualify?

What is the minimum cash requirement to qualify for a NASDAQ listing?

Besides a minimum PPS, what other “items” are required?

This could be a learning experience for me and I TYIA.

IMO and FWIW.